Investigating Management, Perspectives and Attitudes Towards Care in Takayasu Arteritis (TAK-IMPACT)

January 9, 2026 updated by: University of Edinburgh
This study aims to understand the experiences of patients with Takayasu arteritis (TAK) and how physicians manage the condition. To achieve this, two separate questionnaires will be conducted: one for patients and one for physicians.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This study aims to investigate the experiences and perceptions of patients with Takayasu arteritis regarding their disease, as well as the perspectives of physicians regarding the management and treatment of these patients.

Patients with TAK will be invited to complete an anonymous online (Online Surveys) questionnaire, which will take approximately 25 minutes and will consist of multiple-choice and short-answer questions. The questionnaire will ask about their experience with the condition, symptoms, treatments they have received, and any concerns or priorities they have regarding their care.

Physicians who treat TAK will also be invited to complete a separate online questionnaire, taking around 15 minutes and also consisting of multiple-choice and short-answer questions. This will explore how they diagnose and manage TAK, their choice of treatments, and any challenges they face in treating the condition

Study Type

Observational

Enrollment (Estimated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Participants are UK-based

Description

Inclusion Criteria:

For the patient questionnaire:

  • Age ≥ 18 years
  • A formal diagnosis of TAK

For the physician questionnaire

• A physician involved in the management/decision-making for patients diagnosed with TAK

Exclusion Criteria:

For the patient questionnaire:

  • Age < 18 years
  • Lack of a formal diagnosis of TAK
  • Patients without mental capacity or willingness to provide informed consent
  • Not UK based

For the physician questionnaire

  • Not involved in the management/ decision making for patients diagnosed with TAK
  • Not willing to take part
  • Not UK based

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients with Takayasu Arteritis
Other: Questionnaire
An online annoymous questionnaire consisting of short-answer and multiple-choice questions
Physicians Involved in the Management of Patients with Takayasu Arteritis
Other: Questionnaire
An online annoymous questionnaire consisting of short-answer and multiple-choice questions

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient Perspective
Time Frame: Day 1

To understand the lived experiences of individuals with TAK, including their symptoms, health status post-diagnosis, treatment priorities, and concerns.

The questionnaire covers the following topics:

  • Basic background information
  • Living with Takayasu arteritis
  • Changes to health since diagnosis
  • Physical activity and exercise habits- measured by the International Physical Activity Questionnaire (IPAQ)
  • Smoking history
  • Mental well-being- measured by the EQ-5D instrument
  • Nutrition and diet
  • Personal views and priorities on management
Day 1
Physician Perspective
Time Frame: Day 1

To evaluate current clinical management strategies for TAK, identify treatment priorities, and highlight areas of unmet need in clinical practice.

The physician questionnaire covers the following topics:

  • Clinical background and experience with TAK patients
  • Diagnostic and treatment strategies for TAK
  • Consideration of cardiovascular disease risk in TAK management
  • Physician priorities and unmet needs of management
Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Edinburgh

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2025

Primary Completion (Estimated)

March 15, 2027

Study Completion (Estimated)

March 15, 2027

Study Registration Dates

First Submitted

November 14, 2025

First Submitted That Met QC Criteria

January 9, 2026

First Posted (Actual)

January 20, 2026

Study Record Updates

Last Update Posted (Actual)

January 20, 2026

Last Update Submitted That Met QC Criteria

January 9, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 25-EMREC-064

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Takayasu Arteritis

Clinical Trials on Questionnaire

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe